Generic Times Product News

APRIL 01, 2007

Finasteride Tablets USP, 5 mg

Marketed by: Mylan Pharmaceuticals Inc (Pittsburgh, Pa)

Compared to: Proscar Tablets (Merck & Co Inc)

Indication: December 19, 2006?Mylan Laboratories Inc announced that Mylan Pharmaceuticals Inc was granted final FDA approval for its abbreviated new drug application for finasteride tablets USP, 5 mg. These tablets are indicted for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate to improve symptoms and reduce the risk of the need for surgery, including transurethral resection of the prostate and prostatectomy.

Dosage Form: Tablets: 5 mg

For More Information:

Isosorbide Dinitrate 30-mg Tablet

Marketed by: West-ward Pharmaceutical Corp (Eatontown, NJ)

Compared to: Isordil (Wyeth Laboratories)

Indication: February 22, 2006?West-ward Pharmaceutical Corp launched Isosorbide Dinitrate 30-mg tablets. These tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for the product to be useful in aborting an acute anginal episode.

Dosage Form: Tablets (oral): 30 mg; also available are 2.5-and 5-mg sublingual tablets, and 5-, 10-, and 20-mg oral tablets

For More Information: 800-631-2174

Simvastatin Tablets, 5, 10, 20, and 40 mg

Marketed by: Ranbaxy Pharmaceuticals Inc, a wholly owned subsidiary of Ranbaxy Laboratories Ltd (Guragon, India)

Compared to: Zocor Tablets (Merck Research Laboratories)

Indication: December 21, 2006?Ranbaxy Laboratories Ltd announced that it received approval from the FDA to manufacture and market Simvastatin Tablets USP, 5, 10, 20, and 40 mg in the United States. Simvastatin tablets are indicated in the treatment of patients with coronary heart disease (CHD) or at high risk of CHD or for reductions in risk of CHD mortality and cardiovascular events; patients with hypercholesterolemia requiring modifications of lipid profiles; and adolescent patients with heterozygous familial hypercholesterolemia. A simvastatin regimen can be started simultaneously with diet.

Dosage Form: Tablets: 5, 10, 20, and 40 mg

For More Information:

Trandolapril Tablets

Marketed by: Teva Pharmaceuticals (North Wales, Pa)

Compared to: Mavik (Abbott GMBH and Co)

Indication: February 7, 2007?Teva Pharmaceuticals announced the introduction and availability of Trandolapril Tablets. These tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications such as hydrochlorothiazide. Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin-converting enzyme inhibitor, trandolaprilat.

Dosage Form: Tablets: 1, 2, and 4 mg

For More Information: